13 yrs ago one event changed my life. With a lung function of 24% I completed Port Macquarie Ironman. This made me realise that I was not defined by my diagnosis or my disease. I have never looked back. So if you’re looking for some #MondayMotivation watch the video of my race,

Lung cancer and COPD share common risk factors (e.g smoking, genetics, chronic inflammation, abnormal lung repair mechanisms) and COPD is also an independent risk factor for lung cancer, representing the major comorbidity affecting survival in patients with this disease.

My only goal is to keep improving. I may not always achieve my goal but I will never stop trying! #COPD

World NTM Awareness Day may be over, but our mission to raise awareness about nontuberculous mycobacterial (NTM) lung disease is not! While everyone is exposed to NTM, it typically only causes disease in immunocompromised people, people with pre-existing lung conditions like

We did it! The first approved medication for bronchiectasis Brensocatib approved by the FDA in the United States. A great day for patients and the scientific community that made this happen. Thank you Insmed, all investigators and participants multivu.com/insmed/9347351…

🚨Just published!🚨 Perfect timing with FDA approval of brensocatib in bronchiectasis An in-depth investigation into how DPP1 inhibitors affect neutrophils showing novel and potentially beneficial effects on azurocidin1 and receptor expression Merete Long jacionline.org/article/S0091-…

EGPA is inextricably linked to asthma. Current EGPA research focuses on biomarkers of disease activity, as well as therapies that target subtypes which distinguish the mechanisms of hypereosinophilia and vasculitis. Francesca bit.ly/ERSM108

Grateful to GAAPP new patient advocate Mr Mrissat and to Prof Shteinberg for elevating the voice of patients living with #bronchiectasis .

The AIRTIVITY® Study will see if an investigational medicine can target the harmful inflammation that contributes to bronchiectasis. Recruitment is open now. See who qualifies. Learn more: theairtivitystudy.com

#GINA recommends peak expiratory flow monitoring as a simple, affordable alternative to spirometry to monitor asthma variability and control, making management more accessible. Our Desktop Helper No.18 available in multiples languajes. Learn more at: buff.ly/kNuoM0B

Treatable traits! New! We compare inflammation, microbiome, rheology and mucins in asthma, COPD, bronchiectasis, CF and controls. Huge overlap in biology but clear neutrophilic and T2 endotypes in all diseases! Endotypes>disease labels CHEST journal.chestnet.org/article/S0012-…

Symptoms are important in #Bronchiectasis, predicting risk of exacerbations and response to long-term macrolide treatment. Happy to share our last study published today at The Lancet Respiratory Medicine. Thanks a lot James D Chalmers Lídia Perea and all EMBARC thelancet.com/journals/lanre…

Masters student Claire Baker has written a nice review of the role of viruses in bronchiectasis 50% drop in exacerbations during the pandemic (when rhinovirus/flu and other viruses reduced) illustrates how important they are ERS publications UoD Medicine publications.ersnet.org/content/erjor/…

The faces of oxygen therapy are not always what you might expect. Some studies even suggest as many as 5% of patients using oxygen therapy are under the age of 17. Everybody needs oxygen, but some bodies need a little extra! #WorldOxygenDay #OxygenAccessForLife

We're proud to host the COPD Patient Care Map, a dynamic, collaborative tool designed to drive change across the healthcare ecosystem built through a global collaboration between patient advocates and industry partners. Learn more and download the #COPD Patient Care Map:

The major driver of #dupilumab sales is not eczema but rather airways disease. These sales number for #dupilumab show that there is something special about this therapeutic beyond just downregulating T2 inflammation.

One of the best ways along with a good diet, regular exercise, low cholesterol, and good lung function to prevent many chronic diseases such as #dementia is good sleep for 7 hours/night.

Exciting first session at the #ERSCongress highlighting the potential of new therapeutic approaches for people living with #CRSwNP, #asthma and #COPD..

#ECLIPSE #copd still relevant at #ersconference

Learn what’s new in the 2026 GOLD Report! Highlights include a revised chapter on COPD & multimorbidity, updated guidance on exacerbation management, case-finding, treatment algorithms, and vaccinations. Hear directly from the experts on these key updates! November 12–13 |